# 4-Antibody

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/4-antibody

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.4-antibody.com
- Total disclosed funding: $19M
- Latest round: Series A (Jan 15, 2007)
- Investors on record: 6

## About

4-Antibody AG is a biotechnology company specializing in the development of antibody-based therapeutics for cancer treatment, focusing on innovative immuno-oncology solutions.4-Antibody AG is a biotechnology firm based in Basel, Switzerland, dedicated to developing antibody therapeutics. The company was acquired in February 2014 by Antigenics, a portfolio company of Deutsche Bank and various investment firms. The acquisition details were not disclosed. The company has engaged in four total deals, with their most recent funding round being a Series A of CHF 17.000 mn, led by Advent Venture Partners, with total funds raised amounting to CHF 17.000 mn.4-Antibody AG specializes in the discovery and development of immuno-oncology therapeutics. Their core products include antibody therapies aimed at enhancing the immune system's capacity to fight cancer, with a specific focus on combination therapies utilizing various modalities. The company’s lead product, botensilimab, is designed to improve efficacy and tolerability for patients with microsatellite stable colorectal cancer (MSS CRC), addressing significant medical needs within oncology. They market their products across North America, Europe, and other international markets where demand for advanced cancer treatment exists.4-Antibody AG generates revenue primarily through partnerships and collaborations with industry leaders that facilitate their clinical-stage programs. Their revenue model involves B2B transactions, including upfront payments, milestone payments, and royalties from the sales of proprietary products. Collaborations with pharmaceutical companies may also involve joint development and licensing arrangements, particularly for their lead product, botensilimab, which is advancing through clinical development.4-Antibody AG is focused on developing new antibody-based products targeting various cancers, with specific plans for expansion into international markets, particularly North America and Europe. The CHF 17.000 mn raised in their Series A funding will support these initiatives and enhance their product pipeline. Following the acquisition in February 2014, the company continues to align its strategies to leverage its capabilities in immuno-oncology, while aiming for broader market reach and partnerships.

## Funding rounds

- Series A, Jan 15, 2007, $14M — EQT Life Sciences, Advent Venture Partners, BioMed Partners, Grazia Equity, Mulligan Biocapital
- Series A, Aug 21, 2006, $4.8M — BioMed Partners, Life Science Venture Partners, Grazia Equity, Mulligan Biocapital

## Investors

- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Life Science Venture Partners — Series A
- Grazia Equity (https://capitalatlas.ai/funds/grazia-equity) — Series A
- Mulligan Biocapital (https://capitalatlas.ai/funds/mulligan-biocapital) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Series A